HYTERA-COMMUNICATIONS
25.5.2023 17:30:27 CEST | Business Wire | Press release
Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, received the award of “Best use of critical communications in utilities” with its entry “LECO Electricity MCPTT” at the International Critical Communications Awards (ICCAs) 2023 ceremony held in Helsinki, Finland on May 23. The ICCAs, presented by the Critical Communications Association (TCCA), is a highly-anticipated program recognizing the success of products, organizations, and individuals that have pushed boundaries and capabilities within the field of critical communications. Earlier in April, Hytera’s seven entries were shortlisted by ICCAs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005622/en/
Tony Gray, former CEO of TCCA, presenting the ICCA award to Hytera representative (on the right) (Photo: Business Wire)
This Mission-critical Push-to-talk (MCPTT) deployment highlights a clear path for the migration of the private communications network in the utility sector. Working with local partner Dialog Enterprise, Hytera has deployed a customized MCPTT system for LECO, Lanka Electricity Company (Private) Limited. As the rapid-response arm of the Ceylon Electricity Board, LECO provides electrical services to underserved areas and now works with a state-of-the-art radio communications system based on MCPTT over 4G-LTE technology to cover service grids in Galle, Moratuwa, Kalutara, Negombo, Kelaniya, Kotte, and Nugegoda. In the extreme scenario where cellular network coverage is not available, Hytera’s dual-mode rugged radios support device-to-device (D2D) communication empowered by Digital Mobile Radio (DMR) technology. While it proves the versatility of MCPTT to serve utility companies, the project also demonstrates how product innovations, such as dual-mode radios, can win the users’ buy-ins in technology adoption.
“This MCPTT solution operates at a higher priority than Internet services, and also having a device-to-device communication mode are huge pluses for LECO,” said Athula P. De Silva, Chairman of LECO. “Because when connectivity is interrupted due to unforeseeable circumstances–like a sudden violent storm, for instance–we are the professionals whose job it is to bring the network back up. With this, our dispatchers and field engineers are in constant touch since we are in complete control of our own internal communication channel. So, in the event of an outage, power can be restored much faster. If we had chosen the generic mobile voice service or Push-to-talk over Cellular (PoC) instead, our rapid response team’s communications would have been vulnerable to the same disruptive factors and service interruptions as the general public–and that was totally unacceptable. We are the first line of defense against power outages. MCPTT solution is a perfect fit for our requirements.”
Hytera HyTalk MC Mission Critical Services (MCS) system is a multimedia mission-critical communication solution designed for sectors such as public safety, utilities, and transportation. It is fully compliant with the 3GPP MC standards including MCPTT, MCData, and MCVideo. It delivers reliable voice and video communication, high-speed data transfer, and multimedia dispatch services for daily operations. It helps enhance connectivity for better collaboration and improved situational awareness.
Priority Quality of Service (QoS) of HyTalk MC is guaranteed on the servers of the MCPTT platform provider and on the mobile operator's network. This end-to-end QoS ensures that critical communications users are given the highest priority available over any other commercial users. HyTalk MC also enables Professional Mobile Radio (PMR) to LTE interoperability, so that it allows connections among different task forces.
“The award is a great recognition to all the stakeholders of this project, including LECO and Dialog. This case epitomizes how technological advancements are introduced and adopted to empower professionals from the utility sector,” said Ming Kam Wong, deputy GM of Hytera overseas business, who was present at the ICCAs ceremony. “Hytera is humbled to see itself becoming a frequent participant and winner of ICCAs. Thank you to the panel and congratulations to all the winners of ICCAs 2023.”
About Hytera
Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005622/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom